Genmab — Maj 2020
-
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) https://www.globenewswire.com/news-release/2020/05/27/2039066/0/en/Novartis-announces-new-late-breaking-ofatumumab-data-at-EAN-demonstrating-robust-efficacy-and-safety-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-RMS.html
-
-
Tak GB.
-
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more
BioPharmCatalyst (www.biopharmcatalyst.com)
-
UPDATE 1-Roche, Novartis highlight intensifying rivalry in eye disease, MS https://www.reuters.com/article/roche-lucentis-port/update-1-roche-novartis-highlight-intensifying-rivalry-in-eye-disease-ms-idUSL8N2D90NH
-
@Pensionisten please stick with your sommerblomster and stop shaking that tree???
-
Lancet: Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30081-8/fulltext
-
and : Daratumumab: a game changer in myeloma therapy https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30105-8/fulltext#
-
Måske skal vi under 2000...
-
....og så kommer det igen. Er der nogen der ved noget...gevinsthjemtagning...eller noget helt tredje..;-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind